WHO panel to make recommendations on Moderna coronavirus vaccine

A WHO panel of vaccine experts is set to issue recommendations on Moderna's Covid-19 vaccine on Tuesday

WHO
World Health Organization | File
IANS Geneva
2 min read Last Updated : Jan 23 2021 | 2:43 PM IST

Don't want to miss the best from Business Standard?

A World Health Organization (WHO) panel of vaccine experts is set to issue recommendations on Moderna's Covid-19 vaccine on Tuesday.

The WHO had granted emergency use validation for the Pfizer-BioNTech Covid-19 vaccine on December 31, 2020, opening the door for countries to expedite their own regulatory approval processes to import and administer the vaccine.

Now the WHO panel has reviewed data from Moderna's Covid-19 vaccine.

In a media advisory about the next week's event, the WHO said on Friday that the Strategic Advisory Group of Experts (SAGE) on Immunization will make public its interim recommendations to WHO on the use of Moderna Covid-19 (mRNA-1273) vaccine."The recommendations have been agreed at the SAGE extraordinary meeting held on January 21 (Thursday)," said the advisory.

The Moderna Covid-19 vaccine has already been approved for emergency use in several countries, including the US.

The vaccine is administered as two doses, one month apart to prevent Covid-19.

According to a report released by the US Centers for Disease Control and Prevention (CDC) on Friday, over 1,200 adverse events were reported after receipt of Moderna Covid-19 vaccine as of January 10, with 10 cases determined to be anaphylaxis.

Minor adverse events after vaccinations are not uncommon.

While many countries rely on their own regulatory systems for vaccine approvals, some countries with weak system depend on WHO's nod to a great extent for rolling out their national vaccination programmes.

--IANS

gb/ksk/

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusWorld Health OrganizationCoronavirus VaccineCoronavirus Tests

First Published: Jan 23 2021 | 2:40 PM IST

Next Story